光生物调节疗法通过ROS依赖的Src/ERK/STAT3通路上调血小板生成素治疗血小板减少症
该研究探讨光生物调节疗法(PBMT)改善化疗所致血小板减少症(CIT)的机制。动物实验显示PBMT通过活性氧(ROS)依赖的Src/ERK/STAT3通路促进肝细胞TPO表达,从而促进巨核细胞生成和血小板生成,减轻血小板下降。提示PBMT是治疗CIT的潜在策略。
要点
- PBMT通过增加血小板生成防止血小板严重下降,改善CIT。
- PBMT上调肝TPO表达,经ROS依赖的Src/ERK/STAT3通路。
- PBMT为CIT的非侵入性治疗策略提供实验依据。
核心结论
- PBMT通过ROS依赖的Src/ERK/STAT3通路上调肝TPO表达,促进巨核细胞生成和血小板生成,改善CIT。
研究设计与样本
- 采用western blotting、细胞转染、流式细胞术和动物研究等多种方法探索PBMT对血小板生成的作用及机制。
主要发现
- PBMT通过增加血小板生成防止血小板计数严重下降,改善CIT。
- PBMT在血小板减少小鼠模型中显著上调肝脏TPO表达,促进巨核细胞生成和血小板生成。
- PBMT通过Src/ERK/STAT3信号通路上调肝细胞TPO mRNA和蛋白水平。
- ROS生成是PBMT诱导Src激活及其下游效应所必需的。
临床怎么用
- PBMT可能作为化疗所致血小板减少症的非侵入性治疗选择,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chemotherapy-induced thrombocytopenia (CIT) can increase the risk of bleeding, which may delay or prevent the administration of anticancer treatment schedules. Photobiomodulation therapy (PBMT), a non-invasive physical treatment, has been proposed to improve thrombocytopenia; however, its underlying regulatory mechanism is not fully understood. OBJECTIVE: To further investigate the mechanism of thrombopoietin (TPO) in megakaryocytopoiesis and thrombopoiesis. METHODS: Multiple approaches such as western blotting, cell transfection, flow cytometry, and animal studies were utilized to explore the effect and mechanism of PBMT on thrombopoiesis. RESULTS: PBMT prevented a severe drop in platelet count by increasing platelet production, and then ameliorated CIT. Mechanistically, PBMT significantly upregulated hepatic TPO expression in a thrombocytopenic mouse model, which promoted megakaryocytopoiesis and thrombopoiesis. The levels of TPO mRNA and protein increased by PBMT via the Src/ERK/STAT3 signaling pathway in hepatic cells. Furthermore, the generation of the reactive oxygen species was responsible for PBMT-induced activation of Src and its downstream target effects. CONCLUSIONS: Our research suggests that PBMT is a promising therapeutic strategy for the treatment of CIT.
引用
- Wang Q, Chang H, Shen Q, et al. Photobiomodulation therapy for thrombocytopenia by upregulating thrombopoietin expression via the ROS-dependent Src/ERK/STAT3 signaling pathway. J Thromb Haemost. 2021. PMID: 33501731. doi:10.1111/jth.15252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。